A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic?
Al Sandrock's shock departure from Biogen in November sparked speculation about where he would show up next, and the answer came in today – gene therapy specialist Voyager Therapeutics.
Just months after the venture was unveiled, controversial biotechnology company Altos Labs has officially launched with $3 billion in funding secured from investors.